Zydus, Lupin sign pact to distribute Semaglutide weight- loss injections for diabetes care in India: Check details

Zydus Lifesciences on Tuesday announced a licensing and supply agreement with Lupine Limited to expand the availability of diabetes drugs Semaglutide Injection at a dose of 15 mg/3 ml via a user-friendly reusable pen in India.

According to the agreement, Lupine will pay Zydus an initial license fee, as well as milestone-based payments when certain goals are met. This partnership focuses on increasing patient access to cutting-edge diabetes care and chronic weight management solutions.

“Under this agreement, Lupine will have semi-exclusive rights to co-market Zydus’ innovative Semaglutide Injection in the Indian market under the brands Semanext and Lupine’s Livarise,” Zydus said in a statement.

Also Read | Zydus plans to launch obesity vaccine in a new pen device

Zydus says innovative pen device that will make therapy easier

Zydus Lifesciences General Manager Dr. Sharvil Patel said in a statement: “Our life-changing discoveries enable patients to live healthier, more fulfilling lives. Keeping patients’ needs and comfort at the core, the innovative pen device we offer is designed to facilitate treatment and improve quality of life. We are pleased to join hands with Lupine to expand access to this medicine and its new patient-friendly delivery device, thereby expanding its reach across India.”

Zydus said it will market the product under the brands Semaglyntm, Mashematm and Altermetm.

Lupine Managing Director Nilesh Gupta said: “Our partnership with Zydus to market Semaglutide injection in India is an important step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases.”

Also Read | Indian pharma leaders call for collaboration and partnership to spur innovation

“As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and strengthens our focus on meeting unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India,” Gupta added.

Semaglutide is authorized to treat adults with poorly managed Type 2 diabetes in addition to dietary changes and exercise.

It is also approved for long-term weight control in adults when combined with increased physical activity and a calorie-restricted diet.

Zydus receives NMPA approval for Desidustat in China

Zydus Lifesciences announced on Saturday that China’s National Medical Products Administration (NMPA) has authorized its new drug, Desidustat tablets, for the treatment of kidney anemia.

The pharmaceutical company had previously licensed these tablets to a branch of China Medical System Holdings Ltd (CMS).

Notably, CMS International Development and Management Ltd, a subsidiary of CMS, secured exclusive licensing rights from Zydus in 2020.

Decidustat is an oral treatment designed to manage anemia in Chronic Kidney Disease (CKD) patients. This condition is characterized by progressive decline of kidney function, which can ultimately lead to total kidney failure.

“We are encouraged by NMPA’s approval to market the drug in China. Our life-changing discoveries are driven by our commitment to improving patient outcomes and enabling healthier, more fulfilling lives globally,” Zydus Lifesciences MD Sharvil P Patel said in a statement. he said.